CN104583214B - 人类免疫缺陷病毒复制的抑制剂 - Google Patents
人类免疫缺陷病毒复制的抑制剂 Download PDFInfo
- Publication number
- CN104583214B CN104583214B CN201380043596.7A CN201380043596A CN104583214B CN 104583214 B CN104583214 B CN 104583214B CN 201380043596 A CN201380043596 A CN 201380043596A CN 104583214 B CN104583214 B CN 104583214B
- Authority
- CN
- China
- Prior art keywords
- mmol
- tert
- butoxy
- lcms
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCC1c(cc(*2OC(C)(C)C(C)(C)O2)cc2)c2OCC1 Chemical compound CCCC1c(cc(*2OC(C)(C)C(C)(C)O2)cc2)c2OCC1 0.000 description 6
- FCEPMBPRKFZEKD-DXSDROHOSA-N CC(CCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)C(C)Oc1ccc(C)cc1-c1cccc-3c1 Chemical compound CC(CCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)C(C)Oc1ccc(C)cc1-c1cccc-3c1 FCEPMBPRKFZEKD-DXSDROHOSA-N 0.000 description 2
- GUBBSUUWVXDELB-SLVDUWHLSA-N CC(/C=C1/N=C(C)C([C@@H](C(O)=O)OC(C)(C)C)=C(c2c(C)cc3OCCN(CCCCCc4ccccc4-4)c3c2)N1N)c1cc-4ccc1 Chemical compound CC(/C=C1/N=C(C)C([C@@H](C(O)=O)OC(C)(C)C)=C(c2c(C)cc3OCCN(CCCCCc4ccccc4-4)c3c2)N1N)c1cc-4ccc1 GUBBSUUWVXDELB-SLVDUWHLSA-N 0.000 description 1
- SHTARJXBKXRLHD-YWGMWZHNSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)/[O]=C/C=C/COc1ccccc1-c1cccc-2c1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)/[O]=C/C=C/COc1ccccc1-c1cccc-2c1 SHTARJXBKXRLHD-YWGMWZHNSA-N 0.000 description 1
- RWJFMBQQPUZFBB-YTTGMZPUSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)OCCCCOc1ccc(C)cc1-c1cccc-2c1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)OCCCCOc1ccc(C)cc1-c1cccc-2c1 RWJFMBQQPUZFBB-YTTGMZPUSA-N 0.000 description 1
- QNHCUEYHMKHFHZ-RSUXDYMJSA-N CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1c2)c(-c(cc3)cc4c3OCC[C@@H]4CCCCOc3c-4cccc3)[n]1nc2-c1cc-4ccc1 Chemical compound CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1c2)c(-c(cc3)cc4c3OCC[C@@H]4CCCCOc3c-4cccc3)[n]1nc2-c1cc-4ccc1 QNHCUEYHMKHFHZ-RSUXDYMJSA-N 0.000 description 1
- WYJHJSXIVTYJCF-WXCKSCCKSA-N CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc(-c2cc(-c3ccccc3CCC=C)ccc2)n[n]11)c1N(CC1)CCC1(C)/C=C/C=C Chemical compound CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc(-c2cc(-c3ccccc3CCC=C)ccc2)n[n]11)c1N(CC1)CCC1(C)/C=C/C=C WYJHJSXIVTYJCF-WXCKSCCKSA-N 0.000 description 1
- VSSVWSWBAXPTAW-BHVANESWSA-N CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc(-c2cc(-c3ccccc3CCC=C)ccc2)n[n]11)c1N1CCC(C)(COCC=C)CC1 Chemical compound CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc(-c2cc(-c3ccccc3CCC=C)ccc2)n[n]11)c1N1CCC(C)(COCC=C)CC1 VSSVWSWBAXPTAW-BHVANESWSA-N 0.000 description 1
- QYRFWBZEHOWGKT-GXHSSAHRSA-N CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)/C=C/C=C/CCc1ccccc1-c1cccc-2c1 Chemical compound CC(C)(C)O[C@H](C(OC)=O)c(c(C)nc1cc-2n[n]11)c1N(CC1)CCC1(C)/C=C/C=C/CCc1ccccc1-c1cccc-2c1 QYRFWBZEHOWGKT-GXHSSAHRSA-N 0.000 description 1
- MNZYQPOQYYFAGP-UHFFFAOYSA-N CC(C)(C)[O-]c(c(-c1c(CC(OC)=O)c(C)nc2cc(-c3cc(-c(cccc4)c4O)ccc3)n[n]12)c1Cl)cc2c1N(CC=C)CCO2 Chemical compound CC(C)(C)[O-]c(c(-c1c(CC(OC)=O)c(C)nc2cc(-c3cc(-c(cccc4)c4O)ccc3)n[n]12)c1Cl)cc2c1N(CC=C)CCO2 MNZYQPOQYYFAGP-UHFFFAOYSA-N 0.000 description 1
- UUEURGUMLLFHCB-UHFFFAOYSA-N CCCCN(CCCOCC=C)c1c(C(C(OC)=O)OC(C)(C)C)c(C)nc2cc(-c3cc(-c(c(O)c4)ccc4F)ccc3)n[n]12 Chemical compound CCCCN(CCCOCC=C)c1c(C(C(OC)=O)OC(C)(C)C)c(C)nc2cc(-c3cc(-c(c(O)c4)ccc4F)ccc3)n[n]12 UUEURGUMLLFHCB-UHFFFAOYSA-N 0.000 description 1
- JFTCISYZLOUDEY-HOYUZMNJSA-N C[C@@H](CC=C)NC1=C(c2cccc(-c3n[n]4c(N(CC5)CCC5(C)OCC=C)c([C@@H](C(OC)=O)OC(C)(C)C)c(C)nc4c3)c2)C(F)=CCC1 Chemical compound C[C@@H](CC=C)NC1=C(c2cccc(-c3n[n]4c(N(CC5)CCC5(C)OCC=C)c([C@@H](C(OC)=O)OC(C)(C)C)c(C)nc4c3)c2)C(F)=CCC1 JFTCISYZLOUDEY-HOYUZMNJSA-N 0.000 description 1
- OHGLFRRMTJLYEZ-ASMAMLKCSA-N C[C@@H](CC=C)Oc(c(-c1cccc(-c2n[n]3c(N(CC4)CCC4(C)[U]CC=C)c(/C(/C(OC)=O)=[O-]/C(C)(C)C)c(C)nc3c2)c1)c1C)ccc1Cl Chemical compound C[C@@H](CC=C)Oc(c(-c1cccc(-c2n[n]3c(N(CC4)CCC4(C)[U]CC=C)c(/C(/C(OC)=O)=[O-]/C(C)(C)C)c(C)nc3c2)c1)c1C)ccc1Cl OHGLFRRMTJLYEZ-ASMAMLKCSA-N 0.000 description 1
- IWAMSFNYGNTSRC-ROPHLPQBSA-N C[C@@H](CC=C)Oc(c(-c1cccc(-c2n[n]3c(N(CC4)CCC4(C)[U]CC=C)c(CC(OC)=O)c(C)nc3c2)c1)c1)cc(C)c1[I]1CCC1 Chemical compound C[C@@H](CC=C)Oc(c(-c1cccc(-c2n[n]3c(N(CC4)CCC4(C)[U]CC=C)c(CC(OC)=O)c(C)nc3c2)c1)c1)cc(C)c1[I]1CCC1 IWAMSFNYGNTSRC-ROPHLPQBSA-N 0.000 description 1
- PWKDVHTWIQOLIJ-WYOOIXGGSA-N C[C@@H](CCCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)Oc1ccc(C(F)(F)F)cc1-c1cccc-3c1 Chemical compound C[C@@H](CCCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)Oc1ccc(C(F)(F)F)cc1-c1cccc-3c1 PWKDVHTWIQOLIJ-WYOOIXGGSA-N 0.000 description 1
- LLYNGOSRZKSYAX-UDNBHOFDSA-N C[C@@H](CCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)Oc1ccccc1-c1cccc-3c1 Chemical compound C[C@@H](CCCOC(C)(CC1)CCN1c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2cc-3n[n]12)Oc1ccccc1-c1cccc-3c1 LLYNGOSRZKSYAX-UDNBHOFDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683772P | 2012-08-16 | 2012-08-16 | |
| US61/683,772 | 2012-08-16 | ||
| US201361818572P | 2013-05-02 | 2013-05-02 | |
| US61/818,572 | 2013-05-02 | ||
| US13/959,268 | 2013-08-05 | ||
| US13/959,268 US8906929B2 (en) | 2012-08-16 | 2013-08-05 | Inhibitors of human immunodeficiency virus replication |
| PCT/US2013/054532 WO2014028384A1 (en) | 2012-08-16 | 2013-08-12 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104583214A CN104583214A (zh) | 2015-04-29 |
| CN104583214B true CN104583214B (zh) | 2017-06-09 |
Family
ID=50100460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380043596.7A Expired - Fee Related CN104583214B (zh) | 2012-08-16 | 2013-08-12 | 人类免疫缺陷病毒复制的抑制剂 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8906929B2 (https=) |
| EP (1) | EP2888266B1 (https=) |
| JP (1) | JP6214657B2 (https=) |
| KR (1) | KR20150042830A (https=) |
| CN (1) | CN104583214B (https=) |
| AU (1) | AU2013302873B2 (https=) |
| BR (1) | BR112015003175A2 (https=) |
| CA (1) | CA2882077A1 (https=) |
| EA (1) | EA201590358A1 (https=) |
| ES (1) | ES2619960T3 (https=) |
| IL (1) | IL237154A (https=) |
| MX (1) | MX2015001899A (https=) |
| SG (1) | SG11201500887QA (https=) |
| TW (1) | TW201412750A (https=) |
| WO (1) | WO2014028384A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| ES2619708T3 (es) * | 2013-03-13 | 2017-06-26 | VIIV Healthcare UK (No.5) Limited | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| CN105008369B (zh) * | 2013-03-14 | 2017-07-11 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
| EP3105236B1 (en) | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US9932356B2 (en) | 2014-02-12 | 2018-04-03 | Viiv Healthcare Uk (No. 5) Limited | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9834566B2 (en) * | 2014-02-18 | 2017-12-05 | VIIV Healthcare UK (No.5) Limited | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9409922B2 (en) * | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126758A1 (en) * | 2014-02-18 | 2015-08-27 | Bristol-Myers Squibb Company | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| PT3107913T (pt) | 2014-02-19 | 2018-09-28 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| WO2015126376A1 (en) * | 2014-02-19 | 2015-08-27 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9637501B2 (en) | 2014-02-20 | 2017-05-02 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| TWI700284B (zh) | 2015-05-29 | 2020-08-01 | 日商塩野義製藥股份有限公司 | 具有ｈｉｖ複製抑制作用之含氮３環性衍生物 |
| WO2017025913A1 (en) * | 2015-08-10 | 2017-02-16 | VIIV Healthcare UK (No.5) Limited | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3606921B1 (en) | 2017-04-06 | 2022-06-01 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma. |
| EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111653A2 (en) * | 2008-03-05 | 2009-09-11 | Biocryst Pharmaceuticals, Inc. | Antiviral therapeutic agents |
| CN102036996A (zh) * | 2008-03-19 | 2011-04-27 | 百时美施贵宝公司 | 作为hiv整合酶抑制剂的桥接杂环 |
| WO2012033735A1 (en) * | 2010-09-08 | 2012-03-15 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN102459183A (zh) * | 2009-05-15 | 2012-05-16 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| WO2012065963A2 (en) * | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| ES2402322T3 (es) | 2007-11-15 | 2013-04-30 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| ATE541841T1 (de) | 2007-11-15 | 2012-02-15 | Boehringer Ingelheim Int | Inhibitoren der replikation des human immunodeficiency virus |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| EP2215298B1 (en) | 2007-11-23 | 2014-03-26 | Koninklijke Philips N.V. | Compartment |
| GB0813980D0 (en) | 2008-07-31 | 2008-09-10 | Univ St Andrews | Control of relaxation oscillations in intracavity optical parametric oscillato rs |
| JP5331404B2 (ja) | 2008-08-01 | 2013-10-30 | 国立大学法人 東京医科歯科大学 | 先天性異常症の染色体欠失の検出方法 |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| CN102666537A (zh) * | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| SG181423A1 (en) | 2009-12-23 | 2012-07-30 | Univ Leuven Kath | Novel antiviral compounds |
| WO2011121105A1 (en) * | 2010-04-02 | 2011-10-06 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2013
- 2013-08-05 US US13/959,268 patent/US8906929B2/en not_active Expired - Fee Related
- 2013-08-12 SG SG11201500887QA patent/SG11201500887QA/en unknown
- 2013-08-12 MX MX2015001899A patent/MX2015001899A/es unknown
- 2013-08-12 CN CN201380043596.7A patent/CN104583214B/zh not_active Expired - Fee Related
- 2013-08-12 WO PCT/US2013/054532 patent/WO2014028384A1/en not_active Ceased
- 2013-08-12 AU AU2013302873A patent/AU2013302873B2/en not_active Ceased
- 2013-08-12 EA EA201590358A patent/EA201590358A1/ru unknown
- 2013-08-12 JP JP2015527515A patent/JP6214657B2/ja not_active Expired - Fee Related
- 2013-08-12 KR KR20157006290A patent/KR20150042830A/ko not_active Withdrawn
- 2013-08-12 CA CA2882077A patent/CA2882077A1/en active Pending
- 2013-08-12 BR BR112015003175A patent/BR112015003175A2/pt active Search and Examination
- 2013-08-12 EP EP13750479.1A patent/EP2888266B1/en not_active Not-in-force
- 2013-08-12 ES ES13750479.1T patent/ES2619960T3/es active Active
- 2013-08-15 TW TW102129364A patent/TW201412750A/zh unknown
-
2015
- 2015-02-09 IL IL237154A patent/IL237154A/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111653A2 (en) * | 2008-03-05 | 2009-09-11 | Biocryst Pharmaceuticals, Inc. | Antiviral therapeutic agents |
| CN102036996A (zh) * | 2008-03-19 | 2011-04-27 | 百时美施贵宝公司 | 作为hiv整合酶抑制剂的桥接杂环 |
| CN102459183A (zh) * | 2009-05-15 | 2012-05-16 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| WO2012033735A1 (en) * | 2010-09-08 | 2012-03-15 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2012065963A2 (en) * | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
Non-Patent Citations (2)
| Title |
|---|
| "HIV进入抑制剂的研究进展";张浩圆 等;《中国生物工程杂志》;20111231;第31卷(第5期);第113-120页 * |
| "抗HIV药物研究进展及发展趋势";王鹏 等;《海峡药学》;20081231;第20卷(第1期);第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6214657B2 (ja) | 2017-10-18 |
| CN104583214A (zh) | 2015-04-29 |
| AU2013302873B2 (en) | 2017-02-02 |
| AU2013302873A1 (en) | 2015-04-02 |
| EP2888266A1 (en) | 2015-07-01 |
| EA201590358A1 (ru) | 2015-05-29 |
| US20140051692A1 (en) | 2014-02-20 |
| EP2888266B1 (en) | 2017-01-11 |
| IL237154A0 (en) | 2015-04-30 |
| CA2882077A1 (en) | 2014-02-20 |
| JP2015524841A (ja) | 2015-08-27 |
| IL237154A (en) | 2017-03-30 |
| SG11201500887QA (en) | 2015-03-30 |
| ES2619960T3 (es) | 2017-06-27 |
| MX2015001899A (es) | 2015-05-07 |
| KR20150042830A (ko) | 2015-04-21 |
| BR112015003175A2 (pt) | 2017-08-08 |
| TW201412750A (zh) | 2014-04-01 |
| WO2014028384A1 (en) | 2014-02-20 |
| US8906929B2 (en) | 2014-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104583214B (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| CN104781261B (zh) | 黄病毒科病毒的大环抑制剂 | |
| CN104703991B (zh) | 黄病毒科病毒的大环抑制剂 | |
| JP7301000B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| CN104662033B (zh) | 黄病毒科病毒的大环抑制剂 | |
| CN108368084B (zh) | 联芳基激酶抑制剂 | |
| US9580431B2 (en) | Inhibitors of human immunodeficiency virus replication | |
| CN105189503B (zh) | 人免疫缺陷病毒复制的抑制剂 | |
| TWI610916B (zh) | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 | |
| CN103403009B (zh) | 黄病毒科病毒的大环抑制剂 | |
| CN108290843A (zh) | 联芳基激酶抑制剂 | |
| JP2016516692A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| TW201412709A (zh) | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 | |
| TW201615644A (zh) | 作為人類免疫缺乏病毒複製之抑制劑的吡唑并嘧啶巨環化合物 | |
| JP2018519349A (ja) | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 | |
| WO2015126376A1 (en) | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | |
| HK1212349B (en) | Macrocyclic inhibitors of flaviviridae viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170609 Termination date: 20180812 |